Chapter 5: Treatment of tuberculosis disease

References

• Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195. doi:10.1093/cid/ciw376.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. 2017. Licence: CC BY-NC-SA 3.0 IGO.
   Google Scholar
• Johnston JC, Campbell JR, Menzies D. Effect of Intermittency on Treatment Outcomes in Pulmonary Tuberculosis: An Updated Systematic Review and Metaanalysis. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2017;64(9):1211–1220. doi:10.1093/cid/cix121.
   Web of Science ®Google Scholar
• Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLoS Med. 2009;6(9):e1000146. doi:10.1371/journal.pmed.1000146.
   PubMed Web of Science ®Google Scholar
• Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother. 2002;46(2):267–274. doi:10.1128/AAC.46.2.267-274.2002.
   PubMed Web of Science ®Google Scholar
• Mitchison D, Davies G. The chemotherapy of tuberculosis: past, present and future. Int J Tuberc Lung Dis. 2012;16(6):724–732. doi:10.5588/ijtld.12.0083.
   PubMed Web of Science ®Google Scholar
• David HL. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol. 1970;20(5):810–814. doi:10.1128/am.20.5.810-814.1970.
   PubMedGoogle Scholar
• Vernon AA. Chapter 8: Current Standard Treatment. In: Donald PR, van Helden PD, eds. Progress in Respiratory Research. Vol 40. Basel: KARGER; 2011. 61–72.
   Google Scholar
• Forget EJ, Menzies D. Adverse reactions to first-line antituberculosis drugs. Expert Opin Drug Saf. 2006;5(2):231–249. doi:10.1517/14740338.5.2.231.
   PubMed Web of Science ®Google Scholar
• Donald PR, Schaaf HS. Chapter 4: Isoniazid Pharmacokinetics and Efficacy in Adults and Children. In: Donald PR, van Helden PD, eds. Progress in Respiratory Research. Vol 40. Basel: KARGER; 2011. 25–31.
   Google Scholar
• Snider DE. Pyridoxine supplementation during isoniazid therapy. Tubercle. 1980;61(4):191–196. doi:10.1016/0041-3879(80)90038-0.
   PubMedGoogle Scholar
• Burman W, Dooley KE, Nuermberger EL. Chapter 3: The Rifamycins: Renewed Interest in an Old Drug Class. In: Donald PR, van Helden PD, eds. Progress in Respiratory Research. Vol 40. Basel: KARGER; 2011. 18–24.
   Google Scholar
• Campbell JR, Trajman A, Cook VJ, et al. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis. 2020;20(3):318–329. doi:10.1016/S1473-3099(19)30575-4.
   PubMed Web of Science ®Google Scholar
• Laboratory analysis of rifampin/rifapentine products. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/laboratory-analysis-rifampinrifapentine-products. Accessed.
   Google Scholar
• Mitchison DA, Zhang Y. Chapter 5: Recent Developments in the Study of Pyrazinamide: An Update. In: Donald PR, van Helden PD, eds. Progress in Respiratory Research. Vol 40. Basel: KARGER; 2011. 32–43.
   Google Scholar
• Ezer N, Benedetti A, Darvish-Zargar M, Menzies D. Incidence of ethambutol-related visual impairment during treatment of active tuberculosis. Int J Tuberc Lung Dis. 2013;17(4):447–455. doi:10.5588/ijtld.11.0766.
   PubMed Web of Science ®Google Scholar
• Visser ME, Texeira-Swiegelaar C, Maartens G. The short-term effects of anti-tuberculosis therapy on plasma pyridoxine levels in patients with pulmonary tuberculosis. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease. 2004;8(2):260–262.
   PubMed Web of Science ®Google Scholar
• McCUNE R, Deuschle K, McDERMOTT W. The delayed appearance of isoniazid antagonism by pyridoxine in vivo. Am Rev Tuberc. 1957;76(6):1100–1105.
   Google Scholar
• Chen Z, Liang J-Q, Wang J-H, Feng S-S, Zhang G-Y. Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis. Tuberculosis (Edinb)). 2015;95(4):490–496. doi:10.1016/j.tube.2015.03.014.
   Web of Science ®Google Scholar
• Lee HW, Lee JK, Kim E, Yim J-J, Lee C-H. The Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-Analysis. PLOS One. 2016;11(7):e0159827. doi:10.1371/journal.pone.0159827.
   PubMed Web of Science ®Google Scholar
• Dorman SE, Nahid P, Kurbatova EV, Tuberculosis Trials Consortium, et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. N Engl J Med. 2021;384(18):1705–1718. doi:10.1056/NEJMoa2033400.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication: FDA advises restricting fluoroquinolone antibiotic use for certain uncomplicated infections: warns about disabling side effets that can occur together. U.S. Food and Drug Administration. https://www.fda.gov/media/97602/download. Accessed February 23, 2022.
   Google Scholar
• Crabol Y, Catherinot E, Veziris N, Jullien V, Lortholary O. Rifabutin: where do we stand in 2016? J Antimicrob Chemother. 2016;71(7):1759–1771. doi:10.1093/jac/dkw024.
   PubMed Web of Science ®Google Scholar
• Pease C, Hutton B, Yazdi F, et al. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf. 2018;27(6):557–566. doi:10.1002/pds.4423.
   PubMed Web of Science ®Google Scholar
• List of drugs for an Urgent Public Health Need. Government of Canada. https://www.canada.ca/en/health-canada/services/drugs-health-products/access-drugs-exceptional-circumstances/list-drugs-urgent-public-health-need.html. Accessed February 23, 2022.
   Google Scholar
• World Health Organization. Treatment of drug-susceptible tuberculosis: rapid communication. June 14, 2021 2021.
   Google Scholar
• World Health Organization. Concept note: Dose optimization of rifampincin, isoniazid, pyrazinamide and ethambutol in the treatment of drug-susceptbile tuberculosis. World Health Organization. https://www.who.int/docs/default-source/hq-tuberculosis/dose-optimization-concept-note.pdf?sfvrsn=934ab3e2_2. Published 2017. Updated 2017. Accessed February 23, 2022.
   Google Scholar
• Romanowski K, Balshaw RF, Benedetti A, et al. Predicting tuberculosis relapse in patients treated with the standard 6-month regimen: an individual patient data meta-analysis. Thorax. 2019;74(3):291–297. doi:10.1136/thoraxjnl-2017-211120.
   PubMed Web of Science ®Google Scholar
• Imperial MZ, Nahid P, Phillips PPJ, et al. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med. 2018;24(11):1708–1715. doi:10.1038/s41591-018-0224-2.
   PubMed Web of Science ®Google Scholar
• Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. The Lancet Infectious Diseases. 2010;10(6):387–394. doi:10.1016/S1473-3099(10)70071-2.
   PubMed Web of Science ®Google Scholar
• Albanna AS, Smith BM, Cowan D, Menzies D. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J. 2013;42(3):721–732. doi:10.1183/09031936.00180612.
   PubMed Web of Science ®Google Scholar
• Gallardo CR, Rigau Comas D, Valderrama Rodríguez A, Cochrane Infectious Diseases Group, et al. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. The Cochrane Database of Systematic Reviews. 2016;2016(5):CD009913. doi:10.1002/14651858.CD009913.pub2.
   PubMedGoogle Scholar
• Onorato L, Gentile V, Russo A, et al. Standard versus high dose of rifampicin in the treatment of pulmonary tuberculosis: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(6):830–837. doi:10.1016/j.cmi.2021.03.031.
   PubMed Web of Science ®Google Scholar
• Liefooghe R, Suetens C, Meulemans H, Moran MB, De Muynck A. A randomised trial of the impact of counselling on treatment adherence of tuberculosis patients in Sialkot, Pakistan. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease. 1999;3(12):1073–1080.
   PubMed Web of Science ®Google Scholar
• Flores G. The impact of medical interpreter services on the quality of health care: a systematic review. Med Care Res Rev. 2005;62(3):255–299. doi:10.1177/1077558705275416.
   PubMed Web of Science ®Google Scholar
• StopTB Partnership. Every Word Counts: Suggested Language And Usage for Tuberculosis Communications. First Edition. 2013. Available at: https://stoptb.org/assets/documents/resources/publications/acsm/LanguageGuide_ForWeb20131110.pdf. Accessed February 23, 2022.
   Google Scholar
• Alipanah N, Jarlsberg L, Miller C, et al. Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018;15(7):e1002595. doi:10.1371/journal.pmed.1002595.
   PubMed Web of Science ®Google Scholar
• Heuvelings CC, Greve PF, de Vries SG, et al. Effectiveness of service models and organisational structures supporting tuberculosis identification and management in hard-to-reach populations in countries of low and medium tuberculosis incidence: a systematic review. BMJ Open. 2018;8(9):e019642. doi:10.1136/bmjopen-2017-019642.
   PubMed Web of Science ®Google Scholar
• Ngwatu BK, Nsengiyumva NP, Oxlade O, et al. The impact of digital health technologies on tuberculosis treatment: a systematic review. Eur Respir J. 2018;51(1):1701596. doi:10.1183/13993003.01596-2017.
   PubMed Web of Science ®Google Scholar
• Story A, Aldridge RW, Smith CM, et al. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet (London, England). 2019;393(10177):1216–1224. doi:10.1016/S0140-6736(18)32993-3.
   PubMed Web of Science ®Google Scholar
• Karumbi J, Garner P, Cochrane Infectious Diseases Group Directly observed therapy for treating tuberculosis. The Cochrane Database of Systematic Reviews. 2015;2015(5):CD003343. doi:10.1002/14651858.CD003343.pub4.
   PubMedGoogle Scholar
• Tian J-H, Lu Z-X, Bachmann MO, Song F-J. Effectiveness of directly observed treatment of tuberculosis: a systematic review of controlled studies. Int J Tuberc Lung Dis. 2014;18(9):1092–1098. doi:10.5588/ijtld.13.0867.
   PubMed Web of Science ®Google Scholar
• McKay B, Castellanos M, Ebell M, Whalen CC, Handel A. An attempt to reproduce a previous meta-analysis and a new analysis regarding the impact of directly observed therapy on tuberculosis treatment outcomes. PloS One. 2019;14(5):e0217219. doi:10.1371/journal.pone.0217219.
   PubMed Web of Science ®Google Scholar
• Müller AM, Osório CS, Silva DR, Sbruzzi G, de Tarso P, Dalcin R. Interventions to improve adherence to tuberculosis treatment: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2018;22(7):731–740. doi:10.5588/ijtld.17.0596.
   PubMed Web of Science ®Google Scholar
• Hsieh C-J, Lin L-C, Kuo BI-T, Chiang C-H, Su W-J, Shih J-F. Exploring the efficacy of a case management model using DOTS in the adherence of patients with pulmonary tuberculosis. J Clin Nurs. 2008;17(7):869–875. doi:10.1111/j.1365-2702.2006.01924.x.
   PubMed Web of Science ®Google Scholar
• Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet (London, England). 1998;352(9137):1340–1343. doi:10.1016/S0140-6736(98)04022-7.
   Web of Science ®Google Scholar
• Zwarenstein M, Schoeman JH, Vundule C, Lombard CJ, Tatley M. A randomised controlled trial of lay health workers as direct observers for treatment of tuberculosis. Int J Tuberc Lung Dis. 2000;4(6):550–554.
   PubMed Web of Science ®Google Scholar
• MacIntyre CR, Goebel K, Brown GV, Skull S, Starr M, Fullinfaw RO. A randomised controlled clinical trial of the efficacy of family-based direct observation of anti-tuberculosis treatment in an urban, developed-country setting. nt J Tuberc Lung Dis . 2003;7(9):848–854.
   PubMed Web of Science ®Google Scholar
• Walley JD, Khan MA, Newell JN, Khan MH. Effectiveness of the direct observation component of DOTS for tuberculosis: a randomised controlled trial in Pakistan. Lancet (London, England). 2001;357(9257):664–669. doi:10.1016/S0140-6736(00)04129-5.
   PubMed Web of Science ®Google Scholar
• Kamolratanakul P, Sawert H, Lertmaharit S, et al. Randomized controlled trial of directly observed treatment (DOT) for patients with pulmonary tuberculosis in Thailand. Trans R Soc Trop Med Hyg. 1999;93(5):552–557. doi:10.1016/s0035-9203(99)90379-6.
   PubMed Web of Science ®Google Scholar
• Yin J, Yuan J, Hu Y, Wei X. Association between Directly Observed Therapy and Treatment Outcomes in Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis. PloS One. 2016;11(3):e0150511. doi:10.1371/journal.pone.0150511.
   PubMed Web of Science ®Google Scholar
• Zhang H, Ehiri J, Yang H, Tang S, Li Y. Impact of Community-Based DOT on Tuberculosis Treatment Outcomes: A Systematic Review and Meta-Analysis. PloS One. 2016;11(2):e0147744. doi:10.1371/journal.pone.0147744.
   PubMed Web of Science ®Google Scholar
• Mota L, Al-Efraij K, Campbell JR, Cook VJ, Marra F, Johnston J. Therapeutic drug monitoring in anti-tuberculosis treatment: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2016;20(6):819–826. doi:10.5588/ijtld.15.0803.
   PubMed Web of Science ®Google Scholar
• Munsiff SS, Nilsen DM, Fujiwara P. Clinical Policies and Protocols. New York City Department of Health and Mental Hygiene, New York City Department of Health and Mental Hygiene, Bureau of Tuberculosis Control. 2008. http://www1.nyc.gov/site/doh/health/health-topics/tb-hosp-manual.page.
   Google Scholar
• Romanowski K, Baumann B, Basham CA, Ahmad Khan F, Fox GJ, Johnston JC. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. The Lancet Infectious Diseases. 2019;19(10):1129–1137. doi:10.1016/S1473-3099(19)30309-3.
   PubMed Web of Science ®Google Scholar
• Basham CA, Smith SJ, Romanowski K, Johnston JC. Cardiovascular morbidity and mortality among persons diagnosed with tuberculosis: A systematic review and meta-analysis. PloS One. 2020;15(7):e0235821. doi:10.1371/journal.pone.0235821.
   PubMed Web of Science ®Google Scholar
• Allwood BW, Myer L, Bateman ED. A systematic review of the association between pulmonary tuberculosis and the development of chronic airflow obstruction in adults. Respiration; International Review of Thoracic Diseases. 2013;86(1):76–85. doi:10.1159/000350917.
   PubMed Web of Science ®Google Scholar
• Quaife M, Houben RMGJ, Allwood B, et al. Post-tuberculosis mortality and morbidity: valuing the hidden epidemic. Lancet Respir Med. 2020;8(4):332–333. doi:10.1016/S2213-2600(20)30039-4.
   PubMed Web of Science ®Google Scholar
• Vega V, Rodríguez S, Van der Stuyft P, Seas C, Otero L. Recurrent TB: a systematic review and meta-analysis of the incidence rates and the proportions of relapses and reinfections. Thorax. 2021;76(5):494–502. doi:10.1136/thoraxjnl-2020-215449.
   PubMed Web of Science ®Google Scholar
• Nunn AJ, Phillips PPJ, Mitchison DA. Timing of relapse in short-course chemotherapy trials for tuberculosis. The International Journal of Tuberculosis and Lung Disease: The Official Journal of the International Union against Tuberculosis and Lung Disease. 2010;14(2):241–242.
   PubMed Web of Science ®Google Scholar
• Basham CA, Karim ME, Cook VJ, Patrick DM, Johnston JC. Post-tuberculosis mortality risk among immigrants to British Columbia, Canada, 1985-2015: a time-dependent Cox regression analysis of linked immigration, public health, and vital statistics data. Can J Public Health. 2021;112(1):132–141. doi:10.17269/s41997-020-00345-y.
   PubMed Web of Science ®Google Scholar
• Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB. Tuberculosis and chronic respiratory disease: a systematic review. Int J Infect Dis. 2015;32:138–146. doi:10.1016/j.ijid.2014.12.016.
   PubMed Web of Science ®Google Scholar
• Ravimohan S, Kornfeld H, Weissman D, Bisson GP. Tuberculosis and lung damage: from epidemiology to pathophysiology. Eur Respir Rev. 2018;27(147):170077. doi:10.1183/16000617.0077-2017.
   PubMed Web of Science ®Google Scholar
• Migliori GB, Marx FM, Ambrosino N, et al. Clinical standards for the assessment, management and rehabilitation of post-TB lung disease. Int J Tuberc Lung Dis. 2021;25(10):797–813. doi:10.5588/ijtld.21.0425.
   PubMed Web of Science ®Google Scholar
• Simonsen DF, Farkas DK, Søgaard M, Horsburgh CR, Sørensen HT, Thomsen RW. Tuberculosis and risk of cancer: a Danish nationwide cohort study. Int J Tuberc Lung Dis. 2014;18(10):1211–1219. doi:10.5588/ijtld.14.0161.
   PubMed Web of Science ®Google Scholar
• Duko B, Bedaso A, Ayano G. The prevalence of depression among patients with tuberculosis: a systematic review and meta-analysis. Ann Gen Psychiatry. 2020;19:30. doi:10.1186/s12991-020-00281-8.
   PubMed Web of Science ®Google Scholar
• Lönnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk factor for tuberculosis - a systematic review. BMC Public Health. 2008;8:289. doi:10.1186/1471-2458-8-289.
   PubMed Web of Science ®Google Scholar